Brief: Anthera Pharmaceuticals licenses Japan rights for Blisibimod to Zenyaku Kogyo co ltd

Anthera Pharmaceuticals

15/12/2014 14:02

Dec 15 (Reuters) - Anthera Pharmaceuticals Inc  ANTH.O : 
 * Licenses Japan rights for blisibimod to zenyaku kogyo co., ltd 
 * Co, zenyaku kogyo co executed an exclusive license agreement for 
   commercialization of subcutaneous blisibimod in Japan 
 * Says Anthera to receive up to $48 million plus future product margin on 
   commercial supply of blisibimod 
 * Says zenyaku to reimburse Anthera for a portion of future blisibimod 
   worldwide development costs 
 * Funds from partnership expected to substantially reduce anthera's cash 
   expense associated with blisibimod through 2018 
 
 * Source text for Eikon  ID:nPn1gvsLt  
 
 * Further company coverage  ANTH.O   
 ((Bengaluru Newsroom; +1 646 223 8780))